1. 1|Page ( Lung Cancer) , , , 90%-95% (bronchi andbronchioles) () ( . ) ( ) () - ( ) , 5-6 ( ) - ( ) - 2010 222,520 157,300 14 70% 65 , 3% 45 1930 , -,

2. 2|Page 90% 10 2 20 - 10 - , 30 - 2 14% , 25 400 , 15 24 % 3000 ( ) 5 50-90 , , 20000 , , 15 ( 3. 3|Page , , , , , , , , , , , , , , , ) .., .... , ( ) 1 (SCLC) 2- (NSCLC) , - 20% (SCLC) 1% (NSCLC) 80 % - ( 50% ) (Bronchioloalveolarcarcinoma) , 4. 4|Page30 % ( undifferentiated carcinomas) - - 5-10 % - 5% (3-4 .. ) 40 - , ( ) - - 25% . , , ( Dyspnoea), (wheezing), , (hemoptysis) (called Pancoast's syndrome) ( vocal cords) (hoarseness) (dysphagia) , (abscesses, pneumonia) - - , , - Babul (Bone, Adrenal glands, Brain and Liver) , , , - , , (NSCL) (ACTH) , (NSCLC) 5. 5|Page , , , (Mood swing) - , , , , - ( calcified nodules) .. (computerized tomography, computerized axial tomography, or CAT) , .. .. .. .. .. .. , , (Anaphylactic reaction) .. .. ... (Magnetic resonance imaging )... (Tumor) ... , .. , ... (PET Scaning) 6. 6|Page , [18 FDG] ,( vascularization), (receptor status) , , .. ... , ... ... ( short half-lived radioactive drug) , ( ) , , ( ) ... .. ... - .. ... () ... , 7. 7|Page 1 2 , , Fine needle aspiration Cytology (FNAC) .. .. - , , (called a pleural effusion) - , , , - , (SGOT) (SGPT) ... 8. 8|Page , , , , , , ..125 ... , , (Lymph nodes) , , .., , ..., ... Limited-stage (LS) SCLC extensive-stage (ES) SCLC ... TT0 , Tis (Carcinoma in situ)TXT 3. , , T1 2 . T1b T2T1a > 2 . 3 . > 3 . 7 . , * < 2 .. / T2a T2b T3 > 3 . 5 . > 5 . 7 . > 7 . ( ), , , 9. 9|Page T4 < 2 .. / , , , , , , , N N0 (Local Lymph nodes) N1 (ipsilateral) (peribronchial) / (hilar) (intrapulmonary) N2 (ipsilateral mediastinal) N3(contralateral) (mediastinal) , (hilar) (supraclavicular) M M0 M1 (Distant metastasis)M1a(contralateral) , {malignant pleural (or pericardial) effusion} N1b * In anatomy, the carina is a cartilaginous ridge within the trachea that runs anteroposteriorly between the two primary bronchi at the site of the tracheal bifurcation at the lower end of the trachea * For Lung Cancer Staging Calculator click this wonderful link http://staginglungcancer.org/calculator , , , , , , ( ) (palliative ) (adjuvant therapy) - (Neo adjuvant therapy) - (I II) 10%-35% , 10. 10 | P a g e - , 25%-40% ( ) - , - ( wedge resection), (lobectomy ) ( pneumonectomy) - (lymphadenectomy) , , , (Curative), (Palliative) ( ) - , - - , 10%-15% ... , 11. 11 | P a g e .., 30 4 5 - , ( ) (Platelets) ( ) , , - , , , ... , - ( ) ( ) , , , , , , PE 25 mg/m2 IV days 1-3 100 mg/m2 IV days 1-3PEC 200 mg/m2 IV day 1 50 mg/d PO alternating with 100 mg/d PO from days 1-10AUC 6 IV day 1CAV 1000 mg/m2 IV day 1 50 mg/m2 IV day 1 2 mg IV 12. 12 | P a g eCAVE 1000 mg/m2 IV day 1 50 mg/m2 IV day 1 2 mg IV 100 mg/m2 IV day 1 1.5 mg/m2 IV day 1-5 50 mg PO bid days 1-14 ACE (, ) CAV (, ) AUC = area under the concentration curve; bid = twice daily; IV = administered intravenously; PO = administered orally. (Paraplatin) (Taxol) (Taxotere) http://chemoregimen.com/Lung-Cancer-c-43-54.html ( called micrometastasis) , .. ... -(Short termmemory loss), , -, / 13. 13 | P a g e (PDT) ( ) - ( ) , - , ... (Photofrin) ( ) (RFA) - .. - ... (clinical trials) (clinical trials) , 14 , EGFR, ALK KRAS 20% 30% EGFR (Tarceva) (Iressa) , (EGFR) EGFR , ( resistance) 4800 14. 14 | P a g e 2% 7% ALK (anaplastic lymphoma kinase) (1-2% ) (crizotinib) ALK 6 , - - (Avastin) , , EGFR , ( cure) , , , 4-5 5%-10% 15. 15 | P a g e stage 75% 16% - ! 4.48 , , , - , , , , , , ( ) 3 16. 16 | P a g e ( . . 150) () ( . .) 150 .. , 7-12 () 0.5 .. , 1 .. 12 16-24 ( ) 3-6 http://www.drugs.com/quit-smoking.html http://www.drugsupdate.com/brand/showavailablebrands/674 http://www.unitedpharmacies-uk.com/product.php?productid=1373&cat=13&page=7 20 12 2 3 1 9 - - , (cilia) , ( mucus) 1 5 , , , (Cervix) 2-3 10 ( larynx) ( pancreas) 15